Capricor Therapeutics, Inc. · NASDAQ:CAPR

Capricor Therapeutics — Technical Presentation (March 2020)

15 slides from Capricor Therapeutics's technical presentation, Mar 26, 2020

  1. Slide 1: Key Opinion Leader Call – Why Exosomes are Uniquely Suited for Vaccine Development

    Key Opinion Leader Call – March 26, 2020 Why Exosomes are Uniquely Suited for Vaccine Development -Exosomes Platform Technology to Combat the Novel Coronavirus- NASDAQ: CAPR Capricor Therapeutics, Inc. Developing Transformative Therapies from Bench to Bedside

  2. Slide 2: Forward-Looking Statements

    Forward-Looking Statements Statements in this presentation regarding the efficacy, safety, and intended utilization of Capricor's product candidates; the initiation, conduct, size, timing and results of discovery efforts and clinical trials; the pace of enrollment of clinical trials; plans regarding

  3. Slide 3: Call Participants

    Call Participants Stephen J. Gould, Ph.D. – Professor of Biological Chemistry at Johns Hopkins University and Executive Consultant to Capricor Linda Marban, Ph.D. – Capricor CEO Capricor Therapeutics, Inc. Developing Transformative Therapies from Bench to Bedside 3

  4. Slide 4: Stephen J. Gould: Affiliations, Activities, & Conflicts

    Stephen J. Gould Affiliations, Activities, & Conflicts Academic Affiliations & Activities: Consulting: Equity/Royalty/License: Professor of Biological Chemistry Sanderling Ventures TAVEC* Johns Hopkins University ReNeuron Exosoma* Capricor GSC Services* JHU Administrative Activities Gates Ventures C

  5. Slide 5: Johns Hopkins Coronavirus COVID-19 Global Cases (March 7)

    coronavirus.jhu.edu @_ Coronavirus COVID-19 Global Cases by Johns Hopkins CSS Total Deaths Total Recovered Total Confirmed = 3,555 2,959 deaths Hubei Mainlan Hubei Mainland China Confirmed Cases by Country/Region 233 de 145 de Mainland China Henan Mainland China South Korea 44 Guangdong Mainland Chi

  6. Slide 6: Johns Hopkins Coronavirus COVID-19 Global Cases (March 25)

    coronavirus ai Coronavirus COVID-19 Global Cases by the Center for Systems Science and Engineering (CSSE) at Johns Hopkins University (JHU) Total Deaths = = Total Confirmed Total Recovered 20,499 112,982 7,503 60,81 italy Hubei China Confirmed Cases by 9.6 Country/Region/Sovereignty China Iran Hubei

  7. Slide 7: 1. What Are Exosomes/Extracellular Vesicles (EVs)

    1. What Are Exosomes/Extracellular Vesicles (EVs): Secreted, Single Membrane Vesicles Exosomes: • small secreted vesicles,~30-150nm • highly enriched in selected: o proteins o lipids o nucleic acids o glycoconjugates • released by all cells • abundant in biofluids (blood, urine, saliva, milk, CSF, b

  8. Slide 8: 2. How Do Cells Make Exosomes?

    2. How Do Cells Make Exosomes? 8

  9. Slide 9: 3. Exosomes Are Very Large, Yet Really Small

    3. Exosomes Are Very Large, Yet Really Small [light λ = ~400-700 nm] 9

  10. Slide 10: 4. Exosomes A Drug Delivery Vehicle

    4. Exosomes A Drug Delivery Vehicle • Normally, concentration falls dramatically over distance (inverse cube law) • However, concentrations on/in exosomes remain constant, allowing: [ ] @ cell surface [ ] @ 1r [ ] @ 2r 1. Enhanced signaling from a single molecule (concentration, avidity, interfacial

  11. Slide 11: 5. Exosomes Accumulate at Sites of Vascular Leakiness

    5. Exosomes Accumulate at Sites of Vascular Leakiness = Sites of Inflammation, Tumors, & Infection • vascular permeability limit in most tissues is 6-15 nm, ~1 nm @ the BBB • vascular permeability is much higher in the liver, allowing entry of exosomes (~100-200 nm limit) • vascular permeability is

  12. Slide 12: 6a. Exosome Display Vaccines

    6. How Can Exosomes Be Used To Make Vaccines? 6a. Exosome Display Vaccines recombinant product with clear pipeline: • genetically engineered cells • cell platform approved for biologics production • engineered to express exosome-anchored antigens of interest • genetically engineered exosomes • cells

  13. Slide 13: 6b. Exosome-mRNA Vaccines

    6. How Can Exosomes Be Used To Make Vaccines? 6b. Exosome-mRNA Vaccines simple formulation comprised of: • exosomes • released by cells approved for biologics production • purified by scalable filtration and chromatography • mRNAs encoding target antigens • synthesized for stability & high antigen e

  14. Slide 14: 7. Exosome-Based SARS-CoV-2 Vaccines

    7. Exosome-Based SAR2-CoV-2 Vaccines 7a. Exosome-SARS-CoV-2 Display Vaccine: • formulation: exosomes displaying SARS-CoV-2 proteins in their native context • human cell exosomes, recombinant production platform • 4-part antigen design for balanced antigen presentation and immunity • no infection ris

  15. Slide 15: Thank you – Questions and Answers

    Thank you Question and Answers info@capricor.com NASDAQ: CAPR

Capricor Therapeutics — Technical Presentation (March 2020) on 6ix